Chasing BMS, J&J files BCMA CAR-T for multiple myeloma to FDAJohnson & Johnson’s Janssen unit has filed a rolling submission for its multiple myeloma CAR-T ciltacabtagene autoleucel (cilta-cel) Share XChasing BMS, J&J files BCMA CAR-T for multiple myeloma to FDAhttps://pharmaphorum.com/news/chasing-bms-jj-files-bcma-car-t-for-multiple-myeloma-to-fda/
Gene therapy and market access: the pharmaphorum podcastFor episode 10 of the pharmaphorum podcast I spoke to Nicola Redfern, who’s general manager at bluebird bio Share XGene therapy and market access: the pharmaphorum podcasthttps://pharmaphorum.com/podcast/gene-therapy-market-access
How the NHS got ahead of the curve with CAR-TThe UK’s pharma industry has welcomed the NHS’ fast adoption of the latest CAR-T cancer therapies. Richard Staines Share XHow the NHS got ahead of the curve with CAR-Thttps://pharmaphorum.com/views-analysis-oncology/nhs-got-ahead-curve-car-t/
Ahead of the curvePharma often criticises the NHS for failing to adopt the latest therapies, arguing that NICE’s technology appraisals can Share XAhead of the curvehttps://pharmaphorum.com/views-analysis-oncology/ahead-curve-car-t/
Scotland’s TC BioPharm joins bluebird to develop next-gen CAR-TUS cancer biotech bluebird bio has joined with TC BioPharm in a collaboration focused on gamma delta CAR-T Share XScotland’s TC BioPharm joins bluebird to develop next-gen CAR-Thttps://pharmaphorum.com/news/scotlands-tc-biopharma-joins-bluebird-develop-next-gen-car-t/
